CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing a nasal vaccine for avian influenza to enhance pandemic preparedness. Utilizing a chitosan-based technology, it aims to create a heat-stable vaccine that induces both systemic and mucosal immunity, facilitating rapid mass vaccination.
The project is being undertaken in response to the need to develop an effective, user friendly, heat stable vaccine to control the highly pathogenic form of avian influenza virus (H5 and H7 subtypes) which has the potential to cause another global influenza pandemic.
The overall objective of this programme is to develop a nasal avian influenza vaccine using ChiSys® (chitosan), which is a chitosan-based technology of Archimedes Development Ltd..
Chitosan has already been tested with several nasal…
ARCHIMEDES DEVELOPMENT LIMITED
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
United Kingdom, Leicester
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
United Kingdom, LONDON
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Ireland, Dublin
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
